Much experimentation remains in order to elucidate the potential immunomodulatory effect of IFN-β in sepsis therapeutics and to estimate whether, in addition to IFN-β, any other stimulus could aid in efficient immune response reactivation in patients with delayed sepsis. The gene discussed is IFNB1; the disease is Sepsis.